Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ipsen Sa ADR (OP:IPSEY)

48.21 +1.91 (+4.13%)
Streaming Delayed Price Updated: 1:08 PM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ipsen Sa ADR

< Previous 1 2 Next >
News headline image
Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal ↗
In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson. 
Via Talk Markets
Topics Initial Public Offering
News headline image
FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo ↗
The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability... 
Via Benzinga
News headline image
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases ↗
 
Via Benzinga
News headline image
3 Promising Biotech Stocks Flying Under the Radar ↗
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
Via InvestorPlace
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
Virtual Investor Conference on November 8th and 9th, 2023 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs 
Via Benzinga
News headline image
Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class ↗
Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC:  
Via Benzinga
News headline image
Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients ↗
Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT)  
Via Benzinga
News headline image
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur ↗
On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid... 
Via Benzinga
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
From Ipsen
Via Business Wire
News headline image
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
From Ipsen
Via Business Wire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Why These Two Biotech Stocks Blasted Higher This Week ↗
There's nothing like a big-premium buyout to send a company's share price to the moon. 
Via The Motley Fool
News headline image
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday ↗
The market is moving higher, and these small companies are helping. 
Via The Motley Fool
News headline image
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline ↗
 
Via Benzinga
News headline image
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
From Ipsen
Via Business Wire
News headline image
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
From Ipsen
Via Business Wire
News headline image
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study  
Via Benzinga
News headline image
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
From Ipsen
Via Business Wire
News headline image
Why Merrimack Shares Are Surging Over 200% Today? ↗
 
Via Benzinga
News headline image
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
From Ipsen
Via Business Wire
News headline image
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
News headline image
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
From Ipsen
Via Business Wire
News headline image
Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting
From Ipsen
Via Business Wire
News headline image
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
News headline image
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
From Ipsen
Via Business Wire
News headline image
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
From Ipsen
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.